Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties
Reads0
Chats0
TLDR
The generation, mechanism, and development of targetable antibodies or ligands conjugated or fused to toxins or chemicals for direct cell-killing ability, termed immunotoxins or cytotoxic agents are summarized.Abstract:
Despite the progress of the bioinformatics approach to characterize cell-surface antigens and receptors on tumor cells, it remains difficult to generate novel cancer vaccines or neutralizing monoclonal antibody therapeutics. Among targeted cancer therapeutics, biologicals with targetable antibodies or ligands conjugated or fused to toxins or chemicals for direct cell-killing ability have been developed over the last 2 decades. These conjugated or fused chimeric proteins are termed immunotoxins or cytotoxic agents. Two agents, DAB389IL-2 (ONTAKTM) targeting the interleukin-2 receptor and CD33-calicheamicin (Mylotarg), have been approved by the FDA for cutaneous T-cell lymphoma (CTCL) and relapsed acute myeloid leukemia (AML), respectively. Such targetable agents, including RFB4(dsFv)-PE38 (BL22), IL13-PE38QQR, and Tf-CRM107, are being tested in clinical trials. Several agents using unique technology such as a cleavable adapter or immunoliposomes with antibodies are also in the preclinical stage. This review summarizes the generation, mechanism, and development of these agents. In addition, possible future directions of this therapeutic approach are discussed.read more
Citations
More filters
Journal ArticleDOI
Nanoparticle therapeutics: an emerging treatment modality for cancer
TL;DR: The features of nanoparticle therapeutics that distinguish them from previous anticancer therapies are highlighted, and how these features provide the potential for therapeutic effects that are not achievable with other modalities are described.
Journal ArticleDOI
Nanotechnology and cancer.
James R. Heath,Mark E. Davis +1 more
TL;DR: The goal of the presentation is to identify nanotherapeutic strategies that are designed to increase efficacy while simultaneously minimizing the toxic side effects commonly associated with cancer chemotherapies.
Journal ArticleDOI
An overview of targeted cancer therapy.
V. Vijaya Padma,V. Vijaya Padma +1 more
TL;DR: The scope of this review involves the various strategies involved in targeted therapy like-monoclonal antibodies, prodrug, small molecule inhibitors and nano-particulate antibody conjugates.
Journal ArticleDOI
Antibody-targeted nanoparticles for cancer therapy.
TL;DR: An overview of various antibody-conjugated nanoparticle strategies is provided, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.
Journal ArticleDOI
Saporin-S6: A Useful Tool in Cancer Therapy
TL;DR: In this review, some aspects of saporin-S6, such as the chemico-physical characteristics, the structural properties, its endocytosis, its intracellular routing and the pathogenetic mechanisms of the cell damage, are reported.
References
More filters
Journal ArticleDOI
The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins.
TL;DR: The findings indicate that the toxin inactivates the ribosomes by modifying both or either of two nucleoside residues, G4323 and A4324, in 28 S rRNA, in a general mechanistic pathway for ribosome inactivation by lectin toxins.
Journal ArticleDOI
RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes.
Yaeta Endo,Kunio Tsurugi +1 more
TL;DR: The results in the present experiments demonstrated that ricin A-chain inactivates the ribosomes by cleaving the N-glycosidic bond of A4324 of 28 S rRNA in a hydrolytic fashion.
Journal ArticleDOI
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Eric L. Sievers,Richard A. Larson,Edward A. Stadtmauer,Elihu H. Estey,Bob Löwenberg,Hervé Dombret,Chatchada Karanes,Matthias Theobald,John M. Bennett,Matthew L. Sherman,Mark S. Berger,Catharine B. Eten,Michael R. Loken,Jacques J. M. Van Dongen,Irwin D. Bernstein,Frederick R. Appelbaum +15 more
TL;DR: Administration of the antibody-targeted chemotherapy agent Mylotarg to patients with CD33-positive acute myeloid leukemia in first relapse induces complete remissions with what appears to be a favorable safety profile.
Journal Article
Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia
Peter F. Bross,Julie Beitz,Gang Chen,Xiao Hong Chen,Eric Duffy,Lydia Kieffer,S K Roy,Rajeshwari Sridhara,Atiqur Rahman,Grant R. Williams,Richard Pazdur +10 more
TL;DR: Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes, and the reduction of leukocyte counts to below 30,000/ml is recommended prior to treatment.
Journal ArticleDOI
Antibody targeted drugs as cancer therapeutics
TL;DR: Recent preclinical and clinical data for antibody–drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes are discussed.
Related Papers (5)
Anti-cancer activity of targeted pro-apoptotic peptides
H. Michael Ellerby,H. Michael Ellerby,Wadih Arap,Lisa M. Ellerby,Lisa M. Ellerby,Renate Kain,Renate Kain,Rebecca L. Andrusiak,Gabriel del Rio,Gabriel del Rio,Stanislaw Krajewski,Christian R. Lombardo,Rammohan V. Rao,Rammohan V. Rao,Erkki Ruoslahti,Dale E. Bredesen,Dale E. Bredesen,Renata Pasqualini +17 more